Tenaya Therapeutics Inc Cash Flow Conversion Efficiency
Tenaya Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) has a cash flow conversion efficiency ratio of -0.188x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.60 Million) by net assets ($82.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tenaya Therapeutics Inc (2019–2024)
Cash flow conversion efficiency of Tenaya Therapeutics Inc from 2019 to 2024. This chart illustrates how Tenaya Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Tenaya Therapeutics Inc for real-time trading data and today's change.
Tenaya Therapeutics Inc Cash Flow Conversion Ratio Explained
Tenaya Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tenaya Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tenaya Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Tenaya Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JLK Inc
KQ:322510
|
-0.056x |
|
Jasa Armada Indonesia Tbk PT
JK:IPCM
|
0.109x |
|
Jetway Information Co Ltd
TWO:6161
|
0.149x |
|
Qua Granite Hayal Yapi ve Urunleri Sanayi Ticaret AS
IS:QUAGR
|
-0.007x |
|
Morn Sun Feed Mill Corp
TWO:1240
|
0.009x |
|
Tacheng Real Estate Co Ltd
TWO:6171
|
-0.098x |
|
Kuyas Yatirim AS
IS:KUYAS
|
0.042x |
|
Muhibbah Engineering M Bhd
KLSE:5703
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tenaya Therapeutics Inc from 2019 to 2024. Review Tenaya Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.85 Million | $-90.50 Million | -0.975x | -33.13% |
| 2023-12-31 | $139.42 Million | $-102.07 Million | -0.732x | -70.63% |
| 2022-12-31 | $243.38 Million | $-104.42 Million | -0.429x | -96.52% |
| 2021-12-31 | $278.53 Million | $-60.81 Million | -0.218x | +14.11% |
| 2020-12-31 | $139.44 Million | $-35.45 Million | -0.254x | -146.14% |
| 2019-12-31 | $-43.74 Million | $-24.10 Million | 0.551x | -- |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more